Authors: KHAN SA KANIS JA VASIKARAN S KLINE WF MATUSZEWSKI BK MCCLOSKEY EV BENETON MNC GERTZ BJ SCIBERRAS DG HOLLAND SD ORGEE J COOMBES GM ROGERS SR PORRAS AG

Citation: Sa. Khan et al., ELIMINATION AND BIOCHEMICAL RESPONSES TO INTRAVENOUS ALENDRONATE IN POSTMENOPAUSAL OSTEOPOROSIS, Journal of bone and mineral research, 12(10), 1997, pp. 1700-1707

Authors: GERTZ BJ HOLLAND SH KLINE WF MATUSZEWSKI BK FREEMAN A QUAN H LASSETER KC MUCKLOW JC PORRAS AG

Citation: Bj. Gertz et al., STUDIES OF THE ORAL BIOAVAILABILITY OF ALENDRONATE, Clinical pharmacology and therapeutics, 58(3), 1995, pp. 288-298

Authors: CERCHIO K LEWIS G PORRAS AG CAIRNS AM GERTZ BJ POLVINO WJ

Citation: K. Cerchio et al., COMBINATION PHARMACOKINETICS OF DILTIAZEM ER AND ENALAPRIL, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 203-203

Authors: GREBER TF OLAH TV GILBERT JD PORRAS AG HICHENS M

Citation: Tf. Greber et al., DETERMINATION OF L-691,121, A NEW CLASS-III ANTIARRHYTHMIC, AND ITS PRINCIPAL METABOLITE IN PLASMA BY DIFFERENTIAL RADIOIMMUNOASSAY, Journal of pharmaceutical and biomedical analysis, 12(4), 1994, pp. 483-492

Authors: GOLDBERG MR PORRAS AG GREBER TF SOMERS G PRUITT L DESMET M

Citation: Mr. Goldberg et al., MK-499-PLASMA CONCENTRATIONS (PC) AND SUSTAINED EFFECTS ON QT(C) INTERVAL IN HEALTHY-VOLUNTEERS (HV), Clinical pharmacology and therapeutics, 55(2), 1994, pp. 158-158

Authors: GERTZ BJ HOLLAND SD KLINE WF MATUSZEWSKI BK PORRAS AG

Citation: Bj. Gertz et al., CLINICAL-PHARMACOLOGY OF ALENDRONATE SODIUM, Osteoporosis international, 3, 1993, pp. 190000013-190000016